Biopharmaceutical drug pricing and market access contracting has become more complicated and interrelated than ever. The profitability of both pricing decisions and contracting decisions are now firmly linked and a quickly evolving legislative and regulatory shift in the area of state price transparency reporting is further elevating the compliance implications of adjustments in price. Finally, the march from volume-based to value-based commercial models demands the linkage of outcomes and real world data to be linked into this broader solution footprint.
Learn about a more integrated and intuitive approach to linking pricing, contracting, and value-based decisions to create organizational agility and an ability to scale in this quickly changing complex landscape. Join us to discuss how this inter-connected approach can have a radical impact on the profitability of life sciences organizations as well as align incentives across the health care ecosystems.